PMID- 18551065
OWN - NLM
STAT- MEDLINE
DCOM- 20080715
LR  - 20151119
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 85
IP  - 11
DP  - 2008 Jun 15
TI  - Enzyme-linked immunosorbent assay for human leukocyte antigen antibody detection 
      and urine protein test recommended for follow-up monitoring after renal 
      transplantation.
PG  - 1595-600
LID - 10.1097/TP.0b013e318170f79f [doi]
AB  - BACKGROUND: Although the usefulness of posttransplant human leukocyte antigen 
      (HLA) antibody monitoring has been demonstrated, detailed recommendations have 
      not been worked out in its frequency, the type of patients and methods to be 
      used. Enzyme-linked immunosorbent assay is a simple and cost-efficient assay. The 
      urine protein test that reflects renal dysfunction is performed everywhere. We 
      assessed the clinical value of HLA antibody and urine protein monitoring after 
      renal transplantation. METHODS: Serum samples were consecutively collected from 
      outpatients (n=323) in 2004 and in 2006. Because 18 had graft failure and 8 died 
      with functioning graft for 2 years, 297 paired sera were tested for HLA antibody 
      using enzyme-linked immunosorbent assay. Urine protein was determined to be 
      positive when the dipstick protein reaction was+/-or over (20 mg/dL). RESULTS: 
      Total 297 patients were divided according to the change of HLA antibody status. 
      Only patients with all of (i) de novo HLA antibody production, (ii) continuous 
      detection from peripheral blood, and (iii) positive urine protein test had a 
      significantly higher serum creatinine than the others and demonstrated rapid 
      deterioration of Cr (DeltaCr 1.26 mg/dL during 2 years). Negative change of HLA 
      antibody stopped the increase of serum creatinine. CONCLUSION: The status of HLA 
      antibody and urine protein provides useful information on graft prognosis. 
      Although the tempo of graft injury is relatively slow, a yearly routine HLA 
      antibody test for all patients and the attempt to reduce HLA antibody to negative 
      levels is recommended, when HLA antibody is newly detected and urine protein test 
      is positive.
FAU - Kobayashi, Takaaki
AU  - Kobayashi T
AD  - Department of Applied Immunology, Nagoya University School of Medicine, Nagoya, 
      Japan. takakoba@med.nagoya-u.ac.jp
FAU - Katayama, Akio
AU  - Katayama A
FAU - Kohara, Setsuko
AU  - Kohara S
FAU - Nagasaka, Takaharu
AU  - Nagasaka T
FAU - Goto, Norihiko
AU  - Goto N
FAU - Ueki, Tsuneo
AU  - Ueki T
FAU - Uchida, Kazuharu
AU  - Uchida K
FAU - Nakao, Akimasa
AU  - Nakao A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Antibodies)
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
CIN - Nat Clin Pract Nephrol. 2008 Dec;4(12):658-9. PMID: 18852733
MH  - Adult
MH  - Antibodies/*blood
MH  - Biomarkers/blood/urine
MH  - Creatinine/blood
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay/*methods
MH  - Follow-Up Studies
MH  - Graft Rejection/complications/*immunology/urine
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Kidney Failure, Chronic/surgery
MH  - Kidney Transplantation/*immunology
MH  - Middle Aged
MH  - Monitoring, Physiologic/*methods
MH  - Prognosis
MH  - Proteinuria/etiology/*urine
MH  - Retrospective Studies
EDAT- 2008/06/14 09:00
MHDA- 2008/07/17 09:00
CRDT- 2008/06/14 09:00
PHST- 2008/06/14 09:00 [pubmed]
PHST- 2008/07/17 09:00 [medline]
PHST- 2008/06/14 09:00 [entrez]
AID - 00007890-200806150-00019 [pii]
AID - 10.1097/TP.0b013e318170f79f [doi]
PST - ppublish
SO  - Transplantation. 2008 Jun 15;85(11):1595-600. doi: 10.1097/TP.0b013e318170f79f.